Hisamitsu Pharmaceutical Co., Inc.
Hisamitsu Pharmaceutical Co., Inc. Fundamental Analysis
Hisamitsu Pharmaceutical Co., Inc. (HTSUF) shows moderate financial fundamentals with a PE ratio of 16.04, profit margin of 12.55%, and ROE of 7.39%. The company generates $157.6B in annual revenue with strong year-over-year growth of 10.09%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 56.8/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze HTSUF's fundamental strength across five key dimensions:
Efficiency Score
WeakHTSUF struggles to generate sufficient returns from assets.
Valuation Score
ExcellentHTSUF trades at attractive valuation levels.
Growth Score
ExcellentHTSUF delivers strong and consistent growth momentum.
Financial Health Score
ExcellentHTSUF maintains a strong and stable balance sheet.
Profitability Score
WeakHTSUF struggles to sustain strong margins.
Key Financial Metrics
Is HTSUF Expensive or Cheap?
P/E Ratio
HTSUF trades at 16.04 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, HTSUF's PEG of 0.04 indicates potential undervaluation.
Price to Book
The market values Hisamitsu Pharmaceutical Co., Inc. at 1.19 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 19.06 times EBITDA. This signals the market has high growth expectations.
How Well Does HTSUF Make Money?
Net Profit Margin
For every $100 in sales, Hisamitsu Pharmaceutical Co., Inc. keeps $12.55 as profit after all expenses.
Operating Margin
Core operations generate 11.48 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $7.39 in profit for every $100 of shareholder equity.
ROA
Hisamitsu Pharmaceutical Co., Inc. generates $5.85 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Hisamitsu Pharmaceutical Co., Inc. generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Hisamitsu Pharmaceutical Co., Inc. generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
HTSUF converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
16.04
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.04
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.19
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.99
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.009
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.77
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.07
vs 25 benchmark
ROA
Return on assets percentage
0.06
vs 25 benchmark
ROCE
Return on capital employed
0.06
vs 25 benchmark
How HTSUF Stacks Against Its Sector Peers
| Metric | HTSUF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 16.04 | 29.78 | Better (Cheaper) |
| ROE | 7.39% | 792.00% | Weak |
| Net Margin | 12.55% | -23280.00% (disorted) | Strong |
| Debt/Equity | 0.01 | 0.25 | Strong (Low Leverage) |
| Current Ratio | 3.77 | 4.60 | Strong Liquidity |
| ROA | 5.85% | -18077.00% (disorted) | Weak |
HTSUF outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Hisamitsu Pharmaceutical Co., Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
23.47%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
29.88%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
-23.57%
Industry Style: Defensive, Growth, Innovation
Declining